Home / Stocks / Astec Lifesciences Ltd
ASTEC

Astec Lifesciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹552.45

Change

+4.1 (0.75%)

Open

₹545.0

Prev. Close

₹548.35

Day High

₹557.95

Day Low

₹541.55

Volume Analysis

Traded

11,685

Delivered

5,432

Delivery %

46.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (3)

  • •Low return on equity (-25.2%)
  • •Below-average fundamentals quality score (27/100)
  • •Low operating margin (-1.7%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹576.15 ₹567.05 ₹559.75 ₹550.65 ₹543.35 ₹534.25 ₹526.95
Fibonacci ₹567.05 ₹560.79 ₹556.91 ₹550.65 ₹544.39 ₹540.51 ₹534.25
Camarilla ₹556.96 ₹555.46 ₹553.95 ₹550.65 ₹550.95 ₹549.44 ₹547.94

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-22.1%

1 Week

+2.88%

1 Month

-17.04%

3 Months

-8.21%

6 Months

-28.42%

1 Year

-24.74%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-24.28%

Net margin -18.22% × asset turnover 0.56x × equity multiplier 2.38x

Company Overview

Sector

Chemicals

Market Cap

₹1,219 Cr

ROE

-25.2%

Book Value

₹150.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Astec Lifesciences Ltd scores weakly on TopFund's composite fundamentals check within the Chemicals sector, at 27/100. The strongest factor is Corporate Governance (66/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (-25.2%); below-average fundamentals quality score (27/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

27/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

59

Growth

0

Valuation

50

Cash Flow

0

Corporate Governance

66

Momentum

9

Institutional Ownership

12

Business Quality

18

Risk & Volatility

35

Liquidity

27

From Screener.in

  • +Company has reduced debt.
  • −Stock is trading at 3.62 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -4.18% over past five years.
  • −Company has a low return on equity of -26.0% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Astec confirms compliance and no undisclosed events behind recent volume spike.

Exchange has sought clarification from Astec Lifesciences Ltd on November 11, 2026, with reference to Movement in Volume.

Please find enclosed, newspaper publication of Financial Results for the Quarter and Half Year ended September 30, 2026.

Astec Lifesciences approved Q2 and H1 FY27 results; Q2 revenue ₹72.6 crore, PAT loss ₹37.4 crore.

Board approved Q2 FY26 results; standalone loss Rs 3,746.96 lakh, consolidated loss Rs 3,742.78 lakh.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 111 51 154 69 99 94 120 91 74 125 159 84 72
Expenses + 114 69 141 116 118 100 114 102 80 121 149 84 92
Operating Profit -3 -18 13 -46 -20 -6 6 -11 -7 4 9 -1 -20
OPM % -3.1% -36.0% 8.0% -67.0% -20.0% -6.0% 4.6% -12.0% -9.0% 3.2% 6.0% -0.8% -27.0%
Other Income + 1 1 2 1 2 2 1 1 1 -1 3 1 1
Interest 6 6 7 7 9 10 10 11 8 7 8 8 7
Depreciation 9 9 9 9 11 11 12 11 10 11 12 11 11
Profit before tax -18 -32 -1 -62 -39 -25 -16 -33 -24 -16 -8 -19 -37
Tax % -24.0% -24.0% 4.0% -36.0% 0.0% 61.0% 3.0% 0.0% 0.0% 0.0% -2.0% 0.0% 0.0%
Net Profit + -13 -24 -1 -40 -39 -40 -16 -33 -24 -16 -8 -19 -37
EPS in Rs -7 -12 0 -20 -19 -20 -8 -17 -11 -7 -3 -8 -17
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -45 -57 21 -51 -11 85 -22 31 -25 33 33 -8 -2

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 267 233 299 368 431 523 555 677 628 458 381 448 439
Expenses + 213 201 236 299 354 437 443 522 551 464 448 453 446
Operating Profit 54 32 63 69 76 85 112 154 77 -6 -66 -4 -7
OPM % 20.0% 14.0% 21.0% 19.0% 18.0% 16.0% 20.0% 23.0% 12.0% -1.3% -17.0% -1.0% -1.7%
Other Income + -16 4 -8 12 11 12 8 10 13 6 6 3 3
Interest 13 13 12 11 12 13 5 9 21 25 37 35 30
Depreciation 13 10 14 15 19 23 26 34 34 36 44 45 45
Profit before tax 13 12 29 56 56 61 89 121 35 -62 -141 -81 -80
Tax % -17.0% 59.0% 33.0% 37.0% 36.0% 23.0% 27.0% 26.0% 27.0% -24.0% -4.0% 0.0% —
Net Profit + 15 5 19 35 36 48 65 90 26 -47 -135 -81 -80
EPS in Rs 8 3 10 18 18 24 33 46 13 -24 -68 -36 -36
Dividend Payout % 16.0% 0.0% 15.0% 8.0% 8.0% 6.0% 5.0% 3.0% 12.0% 0.0% 0.0% 0.0% —
Sales growth 29 -13 28 23 17 21 6 22 -7 -27 -17 18 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 116 99 119 150 183 227 290 377 400 350 215 368 312
Borrowings + 93 127 127 125 176 99 187 279 341 494 555 449 330
Other Liabilities + 133 85 69 119 83 226 181 221 219 112 92 102 129
Total Liabilities 362 330 334 413 461 572 678 897 979 975 881 942 794
Fixed Assets + 133 95 103 115 167 194 213 340 318 386 499 459 457
CWIP 12 20 8 42 19 24 116 23 127 165 21 20 1
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 216 215 223 256 275 354 349 534 534 424 361 463 337
Total Assets 362 330 334 413 461 572 678 897 979 975 881 942 794
Equity Capital 19 19 20 20 20 20 20 20 20 20 20 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 7 -13 19 65 15 168 -8 24 75 10 -8 -81
Cash from Investing Activity + -19 -17 -18 -49 -52 -74 -73 -104 -113 -135 -15 -4
Cash from Financing Activity + 12 31 -1 -18 37 -95 81 80 38 125 24 94
Net Cash Flow 0 2 1 -3 0 0 0 0 0 0 0 9
Free Cash Flow -13 -39 -1 15 -37 123 -111 -80 -42 -125 -24 -86
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 19 -24 41 116 41 219 13 34 104 -211 20 1,796

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.75% → 71.97%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 22.22% 24.12% 28.85% 28.2% 26.64% 24.53% 24.84% 23.57% 24.82% 24.67% 24.69% 24.67%
Promoters 66.75% 66.75% 66.75% 66.74% 66.74% 70.87% 70.87% 72.42% 71.97% 71.97% 71.97% 71.97%
FII 1.28% 1.25% 1.03% 0.53% 1.2% 0.25% 0.02% 0.0% 0.04% 0.03% 0.01% 0.02%
DII 9.74% 7.88% 3.37% 4.5% 5.4% 4.34% 4.26% 4.01% 3.17% 3.33% 3.33% 3.34%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Chemicals — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Astec Lifesciences Ltd (this stock) 1,219 — 3.65 -25.2%
Indo Borax & Chemical Ltd 1,209 28.5 4.21 10.1%
Platinum Industries Ltd 1,208 26.0 2.62 12.7%
Spic Ltd 1,246 6.53 0.86 15.0%
Ultramarine & Pigments L 1,192 11.9 1.35 8.59%
Excel Industries Ltd 1,246 15.8 0.6 4.62%
India Pesticides Limited 1,333 14.1 1.28 12.5%

Which Mutual Funds Hold Astec Lifesciences Ltd?

Frequently Asked Questions about Astec Lifesciences Ltd

Community Sentiment

What are other investors saying about Astec Lifesciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.